Nektar Receivables Turnover from 2010 to 2025

NKTR Stock  USD 0.91  0.01  1.11%   
Nektar Therapeutics Receivables Turnover yearly trend continues to be relatively stable with very little volatility. Receivables Turnover is likely to grow to 37.82 this year. During the period from 2010 to 2025, Nektar Therapeutics Receivables Turnover destribution of quarterly values had range of 63.6963 from its regression line and mean deviation of  17.34. View All Fundamentals
 
Receivables Turnover  
First Reported
2010-12-31
Previous Quarter
36.02
Current Value
37.82
Quarterly Volatility
20.88383291
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Nektar Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nektar Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 17.6 M, Total Revenue of 160.5 M or Gross Profit of 132.2 M, as well as many indicators such as Price To Sales Ratio of 1.85, Dividend Yield of 0.0 or PTB Ratio of 2.99. Nektar financial statements analysis is a perfect complement when working with Nektar Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Nektar Therapeutics Correlation against competitors.
To learn how to invest in Nektar Stock, please use our How to Invest in Nektar Therapeutics guide.

Latest Nektar Therapeutics' Receivables Turnover Growth Pattern

Below is the plot of the Receivables Turnover of Nektar Therapeutics over the last few years. It is Nektar Therapeutics' Receivables Turnover historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Nektar Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Receivables Turnover10 Years Trend
Very volatile
   Receivables Turnover   
       Timeline  

Nektar Receivables Turnover Regression Statistics

Arithmetic Mean26.65
Geometric Mean18.39
Coefficient Of Variation78.36
Mean Deviation17.34
Median23.55
Standard Deviation20.88
Sample Variance436.13
Range63.6963
R-Value(0.05)
Mean Square Error466.34
R-Squared0
Significance0.87
Slope(0.20)
Total Sum of Squares6,542

Nektar Receivables Turnover History

2025 37.82
2024 36.02
2023 40.02
2022 15.39
2021 4.53
2020 3.93
2019 3.11

About Nektar Therapeutics Financial Statements

Nektar Therapeutics shareholders use historical fundamental indicators, such as Receivables Turnover, to determine how well the company is positioned to perform in the future. Although Nektar Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Nektar Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Nektar Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Receivables Turnover 36.02  37.82 

Pair Trading with Nektar Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Nektar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nektar Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Nektar Stock

  0.54VALN Valneva SE ADR Earnings Call TodayPairCorr
  0.53SRZNW Surrozen WarrantPairCorr
  0.46VIGL Vigil NeurosciencePairCorr
  0.45DMAC DiaMedica TherapeuticsPairCorr
  0.36VERV Verve TherapeuticsPairCorr
The ability to find closely correlated positions to Nektar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nektar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nektar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nektar Therapeutics to buy it.
The correlation of Nektar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nektar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nektar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Nektar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Nektar Stock Analysis

When running Nektar Therapeutics' price analysis, check to measure Nektar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nektar Therapeutics is operating at the current time. Most of Nektar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nektar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nektar Therapeutics' price. Additionally, you may evaluate how the addition of Nektar Therapeutics to your portfolios can decrease your overall portfolio volatility.